

ABBREVIATIONS

AE Adverse event	INH Isoniazid	PLHIV Person living with HIV
AI Active ingredient	IP Intellectual property	POC Point of care
API Active pharmaceutical ingredient	ISFI In situ forming implant	PPC Preferred product characteristics
ART Antiretroviral therapy	ISL Islatravir	PRO-CTCAE Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events
ARV Antiretroviral	ISR Injection site reaction	PZ Pangaea Zimbabwe
AUC Area under the curve	IV Intravenous	QD Once daily
AWC Adequate and well-controlled	IVIVC In vitro-in vivo correlation	R or RFP Rifampin
BA Boronic acid	JHU Johns Hopkins University	R&D Research and development
BDQ Bedaquiline	Ka Absorption rate constant	RBT or RFB Rifabutin
BLA Biologics License Application	Ke Elimination rate constant	RFP Request for proposal
CAB Cabotegravir	LA Long acting	RPT Rifapentine
CAT Catechol	LAI Long-acting injectable	RIF Rifampicin
CDC Centers for Disease Control and Prevention	LaPaL Long-acting technologies Patents and Licences database	RLS Resource-limited setting
CELT Centre of Excellence in Long-acting Therapeutics	LAT Long-acting technology	RNA Ribonucleic acid
CFU Colony forming unit	LEAP Long-acting Extended-release Antiretroviral research resource Program	RPV Rilpivirine
CHAI Clinton Health Action Initiative	LEN Lenacapavir	S Streptomycin
CID Clinical Infectious Diseases	LMIC Low-middle income country	SA Short acting
CMC Chemistry, Manufacturing and Controls	LPAD Limited Population Pathway for Antibacterial and Antifungal Drugs	SBIR Small Business Innovation Research
CS Cycloserine	LPV Lopinavir	SC Subcutaneous
DAIDS Division of AIDS	LTBI Latent tuberculosis infection	SD Single dose
DARQ Diarylquinoline	MAP Microneedle array patch	SDU Southern Denmark University
DDI Drug-drug interaction	MDP Multidomain peptide	SHA Salicylhydroxamic acid
DEL Delaminid	MDR Multi-drug resistant	SOC Standard of Care
DMID Division of Microbiology and Infectious Diseases	MIC Minimum inhibitory concentration	SR Sustained release
DOT Directly observed therapy	MMV Medicines for Malaria Venture	STTR Small Business Technology Transfer
DR Drug resistant	MPP Medicines Patent Pool	TAG Treatment Action Group
DS Drug susceptible	Mtb Mycobacterium tuberculosis	TB Tuberculosis
DTG Dolutegravir	MW Molecular weight	TBD Tuberculosis disease
E Ethambutol	NDA New drug application	TBI Tuberculosis infection
EGPAF Elizabeth Glaser Pediatric AIDS Foundation	NGO Non-governmental organization	TPP Target product profile
EML Essential medicines list	NHP Non-human primate	TPT Tuberculosis prevention therapy
ER Extended release	NI Non-inferior	ULA Ultra-long acting
Eto Ethionamide	NIAMD National Institute of Allergy and Infectious Diseases	UNC University of North Carolina
FACIT Functional Assessment of Chronic Illness Therapy	NIH National Institutes of Health	UNMC University of Nebraska Medical Center
FDA Food and Drug Administration	NOFO Notice of funding opportunity	VDOT Video directly observed therapy
FOA Funding opportunity announcement	NOSI Notice of special interest	WHO World Health Organization
FTC Emtricitabine	NP Nanoparticle	WHOQOL-BREF WHO Quality of Life Brief Version
GFB Ganfaborole	NRA National regulatory authority	Z Parazinamide
GLP Good laboratory practices	NTP National Treatment Program	1HP One month of daily RFT and INH
GMP Good manufacturing practices	OBR Optimized background regimen	3HP Three months of weekly RFT and INH
GRAS Generally recognized as safe	OLI Oral lead in	9H Nine months of daily INH
HBV Hepatitis B virus	PAN-TB Project to Accelerate New Treatments for Tuberculosis	
HCP Healthcare provider	PAS Para-aminosalicylic acid	
HCV Hepatitis C virus	PBA Phenylboronic acid	
HHC Household contact	PBPK Physiology-based pharmacokinetic	
HIV Human immunodeficiency virus	PD Pharmacodynamic	
IM Intramuscular	PEPFAR US President's Emergency Plan for AIDS Relief	
IND Investigational New Drug	PK Pharmacokinetic	